uniQure N.V. (FRA:UQ1)

Germany flag Germany · Delayed Price · Currency is EUR
18.68
-0.66 (-3.39%)
Last updated: Dec 5, 2025, 8:10 AM CET
215.75%
Market Cap 1.14B
Revenue (ttm) 13.42M
Net Income (ttm) -200.41M
Shares Out n/a
EPS (ttm) -3.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 135
Open 18.68
Previous Close 19.34
Day's Range 18.68 - 18.68
52-Week Range 5.76 - 60.50
Beta n/a
RSI 28.56
Earnings Date Feb 27, 2026

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1998
Employees 209
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol UQ1
Full Company Profile

Financial Performance

In 2024, uniQure's revenue was $27.12 million, an increase of 71.17% compared to the previous year's $15.84 million. Losses were -$239.56 million, -22.34% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.